Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue $ 22
Cost of revenue 31
Gross loss (9)
Operating expenses:    
Research and development 541 1,096
Selling, general and administrative 3,576 3,471
Total operating expenses 4,117 4,567
Loss from operations (4,126) (4,567)
Other income (expense):    
Interest expense (2,017) (3)
Loss on extinguishment of warrant liability (504)
Gain on issuance of convertible notes 64  
Change in fair value of warrants 5,606
Change in fair value of notes (117)
Other income
Other expense (1,206)
Total other income (expense) 1,826 (3)
Net loss (2,300) (4,570)
Deemed dividend on Series D preferred stock (6)
Net loss attributable to common stockholders $ (2,416) $ (4,570)
Net loss per share attributable to common stockholders (in Dollars per share) $ (0.08) $ (0.29)
Weighted average shares outstanding, basic and diluted: (in Shares) 29,695,083 15,856,316
Series A Preferred Stock    
Other income (expense):    
Cumulative dividends $ (4)  
Series B Preferred Stock    
Other income (expense):    
Cumulative dividends (20)  
Series D Preferred Stock    
Other income (expense):    
Cumulative dividends $ (86)